Thiogenesis Therapeutics, Corp. is very pleased to announce that, further to its news release of December 18, 2023, it has closed a second and final tranche of its non-brokered private placement,.
Further to its news release of November 20, 2023, Thiogenesis Therapeutics, Corp. is very pleased to announce that it has closed a non-brokered private placement through the issuance of 5,584,167.
Thiogenesis Announces Closing of Non-Brokered Private Placement of Common Shares and Insider Participation streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
San Diego, California (Newsfile Corp. - November 27, 2023) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing sulfur-containing therapeutics for unmet pediatric diseases, today announced the addition of Vincent Stanton Jr., MD to its Scientific Advisory Board ("SAB"). Dr. Stanton was a co-founder of Thiogenesis Therapeutics, Inc., dating back to February 2016.Dr. Vincent Stanton Jr., MD is an entrepreneur and consulta
Thiogenesis Announces Non-Brokered Private Placement of Common Shares streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.